A multi-centre, double-blind, randomised, vehicle-controlled study for a quantitative estimation of hair re-growth in male subjects with androgenetic alopecia treated over 6 month with two ethanolic PSK 3841 solutions (2.5% and 5%)

INTERVENTION: PSK 3841 solutions (2.5% or 5%). CONDITION: Androgenetic alopecia. ; Skin and Connective Tissue Diseases ; Androgenetic alopecia PRIMARY OUTCOME: 1. Total and anagen hair numbers; 2. Safety and tolerability SECONDARY OUTCOME: 1. Investigator hair scalp assessment and patient hair growth questionnaire; 2. Pharmacokinetics of PSK 3841 and its metabolites INCLUSION CRITERIA: 1. Men aged between 18 and 50 years with an androgenetic alopecia rated as Norwood‐Hamilton stage IIIa, IIIv, IV, IVa and V 2. Subjects in good health, with no relevant abnormalities in their medical history, physical examination and vital signs 3. Willingness to refrain from using any hair enhancement products or procedures for the duration of the study